Latest:
Dr. Andikyan on the Rationale of Using HIPEC in Ovarian Cancer
Vaagn Andikyan, MD, discusses the utilization of hyperthermic intraperitoneal chemotherapy in patients with stage III epithelial ovarian cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Christian Marth, MD, PhD
Christian Marth, MD, PhD, is a professor in and head of the Department of Obstetrics and Gynecology at Innsbruck Medical University in Austria.
Latest:
Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer: Five-Year and Post-(Neo)Adjuvant Outcomes From KEYNOTE-775 and LEAP-001
Christian Marth, MD, PhD discusses long-term efficacy and safety results from KEYNOTE-775 and LEAP-001. Data include patients with advanced or recurrent endometrial cancer after prior systemic therapy. Follow-up duration was approximately 5 years for KEYNOTE-775 and 4 years for LEAP-001.
B. Douglas Smith, MD
Latest:
Rapid Readout: Post Hoc Analysis of Responses to Ponatinib in patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial
Dr Smith reviews post-hoc data from the OPTIC trial which assessed the safety and efficacy of ponatinib in patients with CP-CML whose disease was resistant to 2 or more TKIs or who have a T3151 mutation.
J. Michael Guenther, M.D., Surgical Oncologist, St. Elizabeth Physicians, Edgewood, Kentucky
Latest:
DecisionDx®-Melanoma is designed to identify cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy without experiencing early recurrence
Sponsored content by Castle Biosciences, Inc. Dr. Guenther has not been compensated in connection with this article; Dr. Guenther receives compensation for his participation on the Speaker’s bureau for Castle Biosciences.
Nataliya V. Uboha, MD, PhD
Nataliya Uboha, MD, PhD, a medical oncologist at University of Wisconsin Health, as well as an associate professor and researcher in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health
Latest:
Key Takeaways and Future Questions in Perioperative GC/GEJC
Panelists discuss the key takeaways, including the establishment of durvalumab plus FLOT as the new standard requiring proper laparoscopic staging and multidisciplinary care. Future questions focus on optimizing treatment for nonresponders and developing more personalized therapeutic approaches.
Meredith Pelster, MD, MSCI
Latest:
Raising the Bar for KRAS G12C+ Colorectal Cancer Treatment
With 2 KRAS G12C inhibitors showing encouraging results in combination with anti-EGFR agents, there is a ray of hope for patients with recurrent colon cancer–a treatment that may offer patients the chance to make it to important milestones.
Rachel Offenbacher, MD
Rachel Offenbacher, MD, is an attending physician in the Division of Pediatric Hematology, Oncology, and Cellular Therapy Children’s Hospital at Montefiore. She is an assistant professor in the Department of Pediatrics at Albert Einstein College of Medicine and a member of Montefiore Einstein Comprehensive Cancer Center in Bronx, NY.
Latest:
From the Lab to the Clinic: Exploring DFMO’s Potential to Prevent Metastatic Disease in Children With Osteosarcoma and Ewing Sarcoma
DFMO shows promise in reducing metastasis in osteosarcoma and Ewing sarcoma, with phase 2 trials underway to test its role as maintenance therapy.
Jamie L. Studts, PhD
Latest:
How Behavioral Science Informs Empathetic and Effective Lung Cancer Prevention Strategies: With D. Ross Camidge, MD, PhD; and Jamie L. Studts, PhD
Drs Camidge and Studts discuss Dr Studts' career in behavioral science and the importance of integrating lung cancer screening into primary care.
Sharlene Gill, MD, MPH, MBA, FRCPC
Sharlene Gill, MD, MPH, MBA, FRCPC, is a professor in the Department of Medicine in the Division of Medical Oncology at The University of British Columbia in Canada.
Latest:
Dr Gill on a Survey of Patient Experiences and Involvement in Decision-Making in CRC
Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses patient experiences and involvement in decision-making in CRC.